vimarsana.com

Acituzumab News Today : Breaking News, Live Updates & Top Stories | Vimarsana

New Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate (ADC)

- On-Target Effect of Trilaciclib Reduces Rates of Multiple Adverse Events Associated with Sacituzumab Govitecan-Hziy by Over 50% Including Neutropenia, Anemia, and Diarrhea - - Most Enrolled. | May 10, 2023

United statesSacituzumab govitecanSacituzumab govitecan hziyRaj malikInvestor relations corporate communicationsEuropean society for medical oncologyResearch triangle parkExchange commissionTherapeutics incAmerican cancer societyTarget effectTrilaciclib reduces ratesMultiple adverse events associatedIncluding neutropeniaEnrolled patients received priorInitial objective response rate

Gilead Sciences, Inc : Sacituzumab Govitecan Receives Positive CHMP Opinion as 2L Treatment for Adult Patients With Metastatic Triple-Negative Breast Cancer

Recommendation is Based on the Phase 3 ASCENT Study Showing that Sacituzumab Govitecan Significantly Improved Overall Survival in 2L vs. Physician's Choice of Chemotherapy in Metastatic Triple-Negative

United statesUnited kingdomFoster cityGreat britainJacquie rossSacituzumab govitecanMerdad parseyGilead sciencesEuropean commissionGilead sciences incExchange commissionGilead public affairsEuropean medicines agencyCommittee for medicinal products human useMetastatic triple negative breastGovitecan could offer

GILD: Sacituzumab Govitecan Gets Positive CHMP Opinion For Triple-Negative Breast Cancer Treatment

FOSTER CITY (dpa-AFX) - Gilead Sciences Inc. (GILD) said that the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency or EMA adopted a positive opinion for sacituzumab

United statesUnited kingdomGreat britainCommittee for medicinal products humanEuropean medicines agencyEuropean commissionGilead sciences incMedicinal productsHuman useMarketing authorization application

vimarsana © 2020. All Rights Reserved.